ALXN - ALXN Stock Rises After Q3 Results Beat Expectations

ALXN stock is up 6% since Alexion Pharmaceuticals (NASDAQ:ALXN) announced its third-quarter results on Wednesday, which saw a 23% year-over-year rise in revenue to $1.26 billion USD.

Alexion reported Q3 earnings of $2.79 per share, which is a 38% increase from $2.02 in the same period last year and also beat the Zacks Consensus Estimate of $2.49. Moreover, revenues of $1.26 billion USD in the quarter also surpassed the Zacks Consensus Estimate of $1.24 billion USD. Revenues were driven by increased sales of Soliris, which brought in $990.5 million USD in sales ...